Merck Gets FDA Approval to Expand Use of Its Top-Selling Drug, Keytruda

The FDA has approved Merck's Keytruda for treating certain head and neck cancers, potentially reducing the risk of recurrence, progression, or death by 30% compared to existing treatments. This expansion for Merck's top-selling drug, which generated $7.2 billion in Q1 revenue, could significantly impact the treatment landscape for the approximately 72,680 new cases of head and neck cancer expected in 2025.

Analysis

Merck (MRK) has secured a significant regulatory win with the Food and Drug Administration's (FDA) approval for an expanded indication of Keytruda, its leading pharmaceutical product, for the treatment of resectable locally advanced head and neck squamous cell carcinoma in adults whose tumors express PD-L1. This approval is pivotal, as Keytruda already constitutes a substantial portion of Merck's revenue, generating $7.2 billion in the first quarter, nearly half of the company's total sales. Clinical trial data supporting the approval demonstrated a notable 30% reduction in the risk of cancer recurrence, progression, or death compared to current standard treatments, positioning Keytruda favorably within this new patient population. With an estimated 72,680 new cases of head and neck cancer anticipated in 2025 in the U.S., this label expansion opens up a considerable market opportunity. This positive development contrasts with Merck's stock performance, which was down approximately 18% year-to-date prior to this announcement, suggesting the news could be a catalyst for re-evaluation by the market.

Key Decisions for Investors

• Investors should assess this FDA approval as a material positive catalyst for Merck, potentially bolstering Keytruda's already dominant revenue stream and expanding its market penetration.
• Considering Merck's shares were down 18% year-to-date before this news, this approval may warrant a re-evaluation of the stock's current valuation and growth prospects.
• Monitor upcoming earnings reports for specific sales contributions from this new Keytruda indication and its impact on Merck's overall oncology franchise growth.